Core Viewpoint - Janux Therapeutics, Inc. (NASDAQ:JANX) is recognized as a promising immunotherapy stock, particularly following its collaboration with Bristol Myers Squibb, which is expected to enhance its development capabilities in solid tumor oncology [1][2]. Group 1: Collaboration and Agreement - Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic targeting a validated solid tumor antigen [1]. - The agreement stipulates that Janux will handle preclinical development up to IND submission, while Bristol Myers Squibb will manage the IND and subsequent global commercialization [2]. - Janux will remain actively involved in supporting Bristol Myers Squibb through the completion of the first Phase 1 clinical study [2]. Group 2: Company Overview - Janux Therapeutics is a preclinical stage biopharmaceutical company focused on developing therapeutics based on the Tumor Activated T Cell Engager platform technology [3]. - The company specializes in tumor-activated immunotherapies for cancer through two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) [3].

Group 1 - Iovance Biotherapeutics Inc. is recognized as a promising immunotherapy stock by hedge funds, with Goldman Sachs raising its price target to $2 from $1.50 while maintaining a Sell rating [1] - The company announced data showcasing a best-in-class profile for its commercial product Amtagvi, demonstrating unprecedented response rates in a real-world clinical study for advanced melanoma patients [2] - Amtagvi is noted as the first one-time T cell therapy for solid tumor cancer and the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and targeted therapy [3] Group 2 - In a study involving 41 evaluable patients with previously treated advanced melanoma, the physician-assessed confirmed objective response rate for Amtagvi was 44%, with a disease control rate of 73% [4] - Iovance Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing tumor-infiltrating lymphocyte (TIL) therapies, with Amtagvi being its lead product candidate [5]

Core Insights - Novartis AG (NYSE:NVS) is recognized as a leading immunotherapy stock by hedge funds, with positive results from the Phase III ALIGN study for Vanrafia (atrasentan) showing significant improvement in eGFR change compared to placebo [1] - Vanrafia received accelerated approval in the U.S. and China for reducing proteinuria in adults with IgAN, with plans for traditional approval in 2026 [2] - JPMorgan raised the price target for Novartis AG to CHF 135 from CHF 125, maintaining an Overweight rating on the shares [3] Group 1: Clinical Developments - The ALIGN study demonstrated a positive difference in eGFR change from baseline at Week 136, favoring Vanrafia across multiple timepoints and measures of kidney function [1] - Clinically meaningful results were observed at Week 132 compared to placebo, particularly in patients receiving SGLT2 inhibitors [1] - ALIGN study offers the longest follow-up period in pivotal Phase III studies for IgAN, with safety results consistent with previous findings [2] Group 2: Market Position and Analyst Ratings - Novartis AG is involved in developing a range of healthcare and pharmaceutical products, including immuno-oncology research [3] - The company is advancing its multi-asset IgAN portfolio, which includes Fabhalta and the investigational compound zigakibart [2] - JPMorgan's price target increase reflects confidence in Novartis AG's market position and growth potential [3]

Group 1 - Incyte Corporation (NASDAQ:INCY) is recognized as a strong immunotherapy stock by hedge funds, with multiple firms reiterating Buy ratings and raising price targets [1][2][3] - Jefferies set a price target of $120, while Morgan Stanley increased its target to $102 from $94, maintaining an Equal Weight rating [1] - Stifel also raised its price target to $120 from $119, maintaining a Buy rating, while noting a "quiet(ish)" first half but positive long-term outlook [2] Group 2 - Incyte reported Q4 and full-year financial results for 2025, with total revenue of $1.51 billion for the quarter, a 28% increase year-over-year [3] - Full-year revenue reached $5.14 billion, reflecting a 21% growth compared to the previous year, driven by increases in net product revenue and milestone and contract revenue [3] Group 3 - Incyte is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in oncology, hematology, inflammation, and autoimmunity [4]

Core Insights - AstraZeneca PLC (NASDAQ:AZN) is recognized as a promising immunotherapy stock by hedge funds, despite receiving a Sell rating from Deutsche Bank with a price target of £115 [1] Group 1: Clinical Trials and Product Performance - AstraZeneca announced positive results from Phase III KALOS and LOGOS trials for Breztri Aerosphere, demonstrating statistically significant improvements in uncontrolled asthma patients compared to dual-combination inhaled corticosteroid/long-acting beta2-agonist medicines [2] - Breztri also showed clinically meaningful reductions in the annualized rate of severe asthma exacerbations versus ICS/LABA medicines, with no new safety or tolerability concerns identified in the trials [3] Group 2: Company Overview - AstraZeneca is a biopharmaceutical company engaged in the exploration, development, manufacturing, and commercialization of prescription medicines, focusing on novel immuno-oncology treatment approaches [4]

Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a leading immunotherapy stock by hedge funds, reporting strong fiscal Q4 and full year 2025 results, driven by the growth of Biktarvy, Descovy, and the launch of Yeztugo, the first twice-yearly HIV prevention therapy in the country [1] Financial Performance - Total fiscal Q4 revenues increased by 5% to $7.9 billion compared to the previous year, primarily due to higher sales of HIV and Liver Disease products, although this was partially offset by lower sales of Veklury® [2] Analyst Ratings - Following the earnings release, several analysts updated their ratings for Gilead. Needham raised the price target to $170 from $140 while maintaining a Buy rating, and Scotiabank increased its target to $177 from $140, keeping an Outperform rating [3] - BofA also raised its price target to $162 from $154, maintaining a Buy rating, and expressed confidence in the company's growth for 2026 based on strong fiscal Q4 performance [4] Company Overview - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that addresses unmet medical needs [5]

Core Insights - Amgen Inc. (NASDAQ:AMGN) is recognized as a strong immunotherapy stock by hedge funds, but has recently been downgraded to Hold from Buy by Freedom Capital, with a revised price target of $375 from $360, citing fair value and ongoing exclusivity challenges [1][2]. Financial Performance - For fiscal Q4, Amgen reported total revenues of $9.9 billion, reflecting a 9% increase year-over-year, with product sales growing by 7% driven by a 10% increase in volume [3]. - The full-year revenue for 2025 reached $36.8 billion, marking a 10% increase compared to the previous year [3]. Product Developments - The European Commission approved UPLIZNA® as an add-on treatment for adults with generalized myasthenia gravis, providing a new targeted treatment option that may enhance long-term disease control [2].

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as a leading immunotherapy stock by hedge funds [1] - The company announced a partnership with Life Science Cares to combat food insecurity, aiming to invest $30 million and mobilize 30,000 volunteer hours by 2030 [1] Financial Performance - In fiscal Q4, Bristol-Myers Squibb reported a 1% revenue growth to $12.5 billion, with growth portfolio revenue increasing by 16% to $7.4 billion [3] - Full-year revenues reached $48.2 billion, with growth portfolio revenues rising by 17% to $26.4 billion [3] Analyst Ratings - Bernstein maintained a Hold rating on Bristol-Myers Squibb with a price target of $58.00 [2] - Morgan Stanley raised its price target from $37 to $40 while keeping an Underweight rating, citing that 2026 revenue and EPS guidance exceeded consensus due to a higher-than-expected Eliquis guide [2]

Group 1 - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is recognized as a top immunotherapy stock by hedge funds, with RBC Capital maintaining a Hold rating and a price target of $745.00 [1] - Regeneron is expanding its immunology portfolio, with 36 abstracts related to its immunology and inflammation pipeline to be presented at the 2026 AAAAI Annual Meeting [3] - The company reported significant developments, including Phase 3 allergen-specific programs targeting ocular symptoms in adults with cat and birch allergies, and new analyses of Dupixent® across various diseases [4] Group 2 - Guggenheim raised its price target for Regeneron to $975 from $865, maintaining a Buy rating and highlighting key upcoming catalysts such as fianlimab/Libtayo LAG-3 data and an FDA decision for Eylea HD [5] - Regeneron focuses on developing therapies for diseases including cancer, eye disorders, and allergic conditions [6]

Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price target. Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders In another development, Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansio ...